Vaping News

Tasmanian Devils

The Pharmacy Guild Tasmania has spoken out against vaping and made claims that it doesn’t work for smoking cessation – despite a wealth of evidence to the contrary

Share on:

The Tasmanian Branch of the Pharmacy Guild of Australia welcomed the announcement by the state Government to restrict the sale of nicotine-containing vapes to patients with a valid prescription from a GP or nurse practitioner. It went on to make claims that vaping doesn’t work for smoking cessation – despite a wealth of evidence to the contrary.

Tasmanian Guild President Helen O’Byrne joined Tasmanian Health Minister, the Hon Guy Barnett MP at the state Government’s announcement.

Ms O’Byrne said the decision was a common-sense decision to protect the health of Tasmanians, particularly young Tasmanians, who were overrepresented in vape usage statistics.

“There is limited evidence to support the use of vaping products for smoking cessation and nicotine dependence”

Helen O'Byrne, Pharmacy Guild Tasmania President

Pharmacy Guild Tasmania said the changes mean community pharmacies will only be permitted to dispense a nicotine-containing vape to patients who present with a valid prescription.

The change effectively brings to life earlier reform attempted at a Commonwealth level, which was to classify nicotine-containing vapes as Schedule 4 product (Prescription Only). A reform supported by community pharmacists across the country and 63 patient, healthcare and school groups including the Australian Medical Association, the Cancer Council, Lung Foundation Australia, the Public Health Association of Australia, and the Royal Australian College of General Practitioners.

Ms O’Byrne said: “Pharmacists, as healthcare professionals, were concerned about the risk of harm to their patients by the dispensing of a product not approved by the Therapeutics Goods Administration.

“No vaping product has been approved by the TGA based on its safety, efficacy or performance. No vaping product is listed on the Australian Register of Therapeutic Goods.

“There is limited evidence to support the use of vaping products for smoking cessation and nicotine dependence. There is evidence that vaping has long-term patient harms, including cancer, lung-scarring and nicotine addiction.

“1 October 2024 looms large for community pharmacists across the country, as the day they bear the sole burden of supplying a product known to be harmful and addictive to Australians. We didn’t ask for it and we don’t want it in community pharmacy.

“I’m pleased today’s announcement relieves Tasmania’s community pharmacists of this uncertainty.

“On behalf of Tasmania’s community pharmacists, we thank Minister Barnett and his Government for their leadership on this critical public health issue. It’s a decision that sees Tasmania set the standard on the responsible regulation of vapes.”

She continued: “All we want to see is an end to kids vaping. This decision will expedite that outcome and with better regulation.

“Community pharmacists are highly trained health professionals, as health professionals we want to see the end of smoking and vaping.

“As part of community pharmacists working to their full scope of practice, smoking cessation treatment using proven therapeutic goods, is available in other jurisdictions and forms part of the Tasmanian Pharmacist Full Scope of Practice Program and the commitment from the Rockliff Government.”

Photo Credit:

  • Flag photo by engin akyurt on Unsplash

Dave Cross avatar

Dave Cross

Journalist at POTV
View Articles

Dave is a freelance writer; with articles on music, motorbikes, football, pop-science, vaping and tobacco harm reduction in Sounds, Melody Maker, UBG, AWoL, Bike, When Saturday Comes, Vape News Magazine, and syndicated across the Johnston Press group. He was published in an anthology of “Greatest Football Writing”, but still believes this was a mistake. Dave contributes sketches to comedy shows and used to co-host a radio sketch show. He’s worked with numerous start-ups to develop content for their websites.

Join the discussion